Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. 1979

M Sheppard, and B Shapiro, and B Pimstone, and S Kronheim, and M Berelowitz, and M Gregory

The MCR and half-disappearance time of exogenously administered somatostatin have been measured during and after cessation of a constant infusion. Studies were performed on normal volunteers and patients with chronic liver disease and failure. Immunoreactive somatostatin was measured by a sensitive and specific RIA using an antiserum directed against the core of the molecule. Normal subjects had a mean MCR of 1949 +/- 250 ml/min (28.4 +/- 4.2 ml/min . kg BW) (mean +/- SEM), similar to values found in five patients with chronic liver disease. However, patients with chronic renal failure showed a highly significant (P less than 0.001) lowering of the MCR (501 +/- 32.7 ml/min or 7.8 +/- 0.6 ml/min . kg). The rate of disappearance of somatostatin after infusion was linear for 7-10 min, after which a much slower component was observed. In normal subjects, the t 1/2 of the first component varied from 1.1-3.0 min, in patients with liver disease it varied from 1.2-4.8 min, and in patients with chronic renal failure it varied from 2.6-4.9 min. Exogenously administered somatostatin is rapidly cleared in normal subjects and patients with chronic liver disease, but the MCR in end stage chronic renal failure is markedly lowered. The kidney may have a role in the metabolic clearance of exogenously administered somatostatin, or uremia may impair catabolism nonspecifically.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008107 Liver Diseases Pathological processes of the LIVER. Liver Dysfunction,Disease, Liver,Diseases, Liver,Dysfunction, Liver,Dysfunctions, Liver,Liver Disease,Liver Dysfunctions
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M Sheppard, and B Shapiro, and B Pimstone, and S Kronheim, and M Berelowitz, and M Gregory
June 1982, The Journal of clinical endocrinology and metabolism,
M Sheppard, and B Shapiro, and B Pimstone, and S Kronheim, and M Berelowitz, and M Gregory
January 1980, Materia medica Polona. Polish journal of medicine and pharmacy,
M Sheppard, and B Shapiro, and B Pimstone, and S Kronheim, and M Berelowitz, and M Gregory
December 1983, The Journal of clinical endocrinology and metabolism,
M Sheppard, and B Shapiro, and B Pimstone, and S Kronheim, and M Berelowitz, and M Gregory
March 1979, The Journal of clinical endocrinology and metabolism,
M Sheppard, and B Shapiro, and B Pimstone, and S Kronheim, and M Berelowitz, and M Gregory
December 1986, Endocrinologia japonica,
M Sheppard, and B Shapiro, and B Pimstone, and S Kronheim, and M Berelowitz, and M Gregory
February 1977, The Journal of clinical endocrinology and metabolism,
M Sheppard, and B Shapiro, and B Pimstone, and S Kronheim, and M Berelowitz, and M Gregory
January 1981, Acta endocrinologica,
M Sheppard, and B Shapiro, and B Pimstone, and S Kronheim, and M Berelowitz, and M Gregory
September 1981, Gut,
M Sheppard, and B Shapiro, and B Pimstone, and S Kronheim, and M Berelowitz, and M Gregory
August 1976, Gut,
M Sheppard, and B Shapiro, and B Pimstone, and S Kronheim, and M Berelowitz, and M Gregory
January 1973, Scandinavian journal of gastroenterology,
Copied contents to your clipboard!